EPO and chronic kidney disease: The present work aimed to study the mechanisms underlying the hyporesponse to endogenous EPO, as well as the impact of long-term treatment of anemia with high rHuEPO doses leading to antibody mediated erythroid hypoplasia, in a rat model of CKD induced by 5/6 nephrectomy previously characterized by us [29].